Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Clinical trial NCT07557420 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07557420
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-31
- Primary completion
- 2028-10-31
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.